To analyze Isosorbide Mononitrate in human plasma, a highly sensitive and accurate LC–MS/MS bioanalytical method was developed and validated using Isosorbide mononitrate-[13]C6 as the internal standard. Validate a suitable analytical method for the estimation of unknown drug concentrations in plasma. It can be used for the quantitation of isosorbide mononitrate in K2EDTA human plasma for bioequivalence and bioavailability studies. The method was found to be specific, sensitive, linear, precise, accurate, and reproducible for the extraction and analysis of isosorbide mononitrate in K2EDTA human plasma samples over the investigated concentration range of 5.000 ng/mL to 1800.000 ng/mL using a processing volume of 0.100 mL. Chromatographic separation was achieved using a 2 mM ammonium acetate (acidified) mobile phase with acetonitrile containing 0.1% acetic acid in a ratio of 55:45 (v/v) at a flow rate of 0.5 mL/min. Detection was carried out using multiple reaction monitoring with transitions (m/z) of 249.90 → 59.00 for isosorbide mononitrate and 255.90 → 58.90 for the internal standard. The analytes were detected using tandem mass spectrometry (LC–MS/MS). The proposed method was comprehensively validated in terms of linearity, accuracy, precision, specificity, sensitivity, recovery, and stability, with results meeting the acceptance criteria. The developed and validated method was found to be simpler, faster, more specific, precise, and cost-effective compared with previously reported methods.

Patient and public involvement and engagement (PPIE) improves research quality but is often limited in scale. This study explored the potential for large-scale PPIE using a Web-based approach.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer death worldwide. Sonodynamic therapy (SDT) offers a non-invasive, deep-penetrating approach by using ultrasound to activate sonosensitizers and generate cytotoxic reactive oxygen species (ROS). Yet poor intratumoral delivery and low ROS quantum yields of existing agents have stalled clinical translation. Here, we present a synergistic SDT platform that overcomes these barriers by combining transient vasodilation of tumor microvessels with the clinically widely used Antianginal drug isosorbide mononitrate and an acceptor-donor-acceptor-donor-acceptor type organic nanosonosensitizer (BTz) engineered for a narrow bandgap and enhanced ultrasound responsiveness. Isosorbide mononitrate increases nanosonosensitizer accumulation by ~ 1.8-fold. Under ultrasound irradiation, nanosonosensitizer produced high ROS generation, resulting in 78% tumor growth inhibition in murine HCC models-nearly double that of SDT alone-without detectable systemic toxicity. Crucially, the near-infrared fluorescence of nanosonosensitizer enabled real-time, image-guided tracking of sonosensitizer uptake and therapeutic response. By repurposing a safe vasodilator and integrating it with a high-performance organic sonosensitizer, this work establishes a readily translatable, minimally invasive paradigm for precise SDT of localized, inoperable or metastatic HCC.